Author: Radhika Shah
Radhika is a PharmD student at Rutgers University. Her passion for the pharmaceutical industry came from realizing how much innovation there is in this field. She is committed to advocating for technological innovation in the pharmaceutical and biotech fields through her writing.
Last week, President and Co-Founder Sumayah Jamhal presented her company, ENB Therapeutics, at the 2023 Immuno-Oncology 360 Degree Conference in New York City. ENB Therapeutics is a clinical stage, privately held company creating therapies to treat drug resistant cancer by reprogramming the tumor microenvironment. Their lead product, ENB-003 is a first-in-class small molecule, selective endothelin receptor type B (ETBR) inhibitor. ENB-003 is currently in its’ phase 1 clinical trial with Merck. The ETBR is present on the luminal surface of tumor blood vessels which downregulate ICAM-1, an adhesion molecule. ENB-003, a ETBR blocker, restores ICAM-1 expression, which allows T-cells to…
Value-based care is the cornerstone of improved quality outcomes for patients. Treating patients is no longer just about fixing the primary problem but on making healthcare proactive by preventing problems before they start. Value-based programs have already been put in place to reward healthcare providers for the quality of care they give to patients and not the quantity of care resulting in better health populations and with lower costs of healthcare. Two women CEOs at the helm of the largest pharmacy chains, Walgreens and CVS, presented at this year’s JPMorgan healthcare conference to discuss what steps they are taking in 2023 to…
After a bullish 2021, characterized by a flow of M&A deals and IPOs, this year company valuations were in correction, financing was at a premium and deals slowed- all of which were most evident for early-stage companies. Still, in 2022, biotech continued to forge ahead as the leading driver of innovation and growth in biopharma. Venture capital made moves on indicative signals while fundamentals remained strong for big pharma to fuel (mostly moderate) M&A transactions and strategic partnerships critical to achieving biotech growth milestones. As we close out the year, we reflect on an industry that still performed with significant…
Smart Immune is a clinical-stage biotechnology startup headquartered in France, developing a thymus-empowered T-cell therapy platform called ProTcell Platform. The company’s mission is to fight cancer and infection by fully and rapidly re-arming the immune system. The ProTcell Platform is a pioneered, allogenic, thymus-empowered T-cell therapy platform. ProTcell reinvigorates the thymus by introducing healthy allogeneic T-cell progenitors into the patient. Through ex-vivo technology, Smart Immune can provide large numbers of T-cell progenitors from hematopoietic stem cells in only seven days. Under normal circumstances, this would take one year in the body. Once infused into the patient, the thymus then educates…
Chronic kidney disease (CKD) affects more than 1 in 7 U.S. adults and approximately 2 in 1,000 Americans live with end-stage kidney disease. Treatment for kidney failure is either receiving a kidney transplant or dialysis. Dialysis can be challenging for patients as it requires a significant time commitment. Patients are dealt with planning their daily life around their dialysis appointments which are usually 3 times a week and can last around 4 hours. Patients who require dialysis also may not have adequate means of transportation to the dialysis clinic. Due to these challenges, home dialysis is an emerging option for…
Hope for Patients Diagnosed with Rare, Aggressive Desmoid Fibromatosis Last month, SpringWorks Therapeutics announced their promising data from the Phase 3 DeFi trial evaluating Nirogacestat at the European Society of Medical Oncology Congress. SpringWorks Therapeutics founded by Lara Sullivan, Danielle Lynch, Stephen Squinito, Saqib Islam, and L. Mary Smith, is a clinical-stage biopharmaceutical company that takes a precision medicine approach to acquire, develop, and commercialize life-changing medicine. Their current focus is on patients with rare tumors, hematological cancers, and biomarker-defined metastatic solid tumors. Nirogacestat is an oral small molecule gamma-secretase inhibitor (GSI) in Phase 3 development for adult patients with…
More than half of the world population lacked access to essential health services even before the COVID-19 pandemic. People living in rural communities often have to travel far to the nearest medical center. The importance of preventative health care is essential and can eliminate the many consequential diseases that can occur. Some barriers to providing health care include a shortage of healthcare staff and difficulty getting into rural and forested areas. A solution to this problem that has been trialed in several countries is medical delivery drones. A drone is an unmanned ariel vehicle that can fly over long distances.…
June is recognized as World Infertility Awareness Month. As many as 48.5 million couples experience some form of infertility due problems related to female and male fertility. There are several current barriers to healthcare in women which include lack of awareness, cost, and gaps in medical training. Current fertility treatment options include in vitro fertilization (IVF), donor eggs, surrogacy, egg freezing, and hormone therapy. As awareness in infertility is increasing more employers recognizes the medical need for treatment and are offering fertility benefits. Below are six emerging startups focusing on women’s reproductive health to look out for in 2022: 1.…
Intra-Cellular Therapies ended the year 2021 with a big achievement. On December 20, 2021, Dr. Sharon Mates, Chairman, and CEO of Intra-Cellular Therapies announced the FDA approval of their medication, CAPLYTA. CAPLYTA (lumateperone) is currently the only medication approved to treat depressive disorders associated with bipolar I or bipolar II as monotherapy and in adjunct with lithium or valproate. Intra-Cellular Therapies is a biopharmaceutical company headquartered in New York focusing treatment of complex psychiatric and neurologic diseases such as schizophrenia, bipolar depression, major depressive disorder, and Parkinson’s disease. The recent FDA approval makes this Intra-Cellular Therapies’ second approved indication for…
LambdaVision is a biotech company, that is designing and developing a protein-based artificial retina. This retina will utilize a light-activated protein, bacteriorhodopsin to restore function sight to those who are blind due to retinal degenerative diseases, including age-related macular degeneration (AMD) and retinitis pigmentosa (RP).
Biotech Metropolitan Women ©2018-2023